These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19546019)

  • 1. Implementation of osteoporosis screening guidelines in prostate cancer patients on androgen ablation.
    Van Tongeren LS; Duncan GG; Kendler DL; Pai H
    J Clin Densitom; 2009; 12(3):287-91. PubMed ID: 19546019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral or axial bone density measurements to identify osteoporosis in prostate cancer patients undergoing androgen deprivation therapy?
    Wadhwa VK; Parr NJ
    Urology; 2009 Jun; 73(6):1347-51. PubMed ID: 19362345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening and treatment of glucocorticoid-induced osteoporosis in rheumatoid arthritis patients in an urban multispecialty practice.
    Ledwich LJ; Clarke K
    J Clin Rheumatol; 2009 Mar; 15(2):61-4. PubMed ID: 19265346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compliance with radiation treatment guidelines in a provincial setting.
    Jackson SM; Baerg B
    Cancer Prev Control; 1999 Jun; 3(3):196-201. PubMed ID: 10474767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoporosis: evaluation of screening patterns in a primary-care group practice.
    Cohen K; Maier D
    J Clin Densitom; 2008; 11(4):498-502. PubMed ID: 18835537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
    Spanjol J; Maricić A; Valencić M; Oguić R; Krpina K; Protić A; Ivancić A; Bobinac M; Fuckar D; Vojniković B
    Coll Antropol; 2008 Oct; 32 Suppl 2():79-81. PubMed ID: 19138011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines do help change behavior in the management of osteoporosis by gastroenterologists.
    Kane S; Reddy D
    Am J Gastroenterol; 2006 Aug; 101(8):1841-4. PubMed ID: 16817840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of treatment guidelines and implementation of a quality assurance program on quality of care in endometrial cancer.
    du Bois A; Strutas D; Buhrmann C; Traut A; Ewald-Riegler N; Kommoss S; Gomez R; Harter P
    Onkologie; 2009 Sep; 32(8-9):493-8. PubMed ID: 19745593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects by androgen suppression with luteinizing hormone on cognitive functions in men treated for cancer of prostate].
    Nedelec C; Ragot S; Irani J; Pires C; Gil R; Doré B
    Prog Urol; 2009 Jan; 19(1):47-53. PubMed ID: 19135642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for osteoporosis in men: comment on the American College of Physicians clinical guidelines.
    Hochberg MC; Adler RA
    Nat Clin Pract Rheumatol; 2008 Dec; 4(12):626-7. PubMed ID: 18839012
    [No Abstract]   [Full Text] [Related]  

  • 13. Approaches to osteoporosis: screening and implementing treatment in clinical practice.
    Rawlins S
    J Fam Pract; 2009 Jul; 58(7 Suppl Osteoporosis):S39-44. PubMed ID: 19825318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Osteoporosis: what about the new guidelines?].
    Weiss J
    Dtsch Med Wochenschr; 2006 Oct; Suppl 1():41-2. PubMed ID: 17595818
    [No Abstract]   [Full Text] [Related]  

  • 15. Cancer chemotherapy-induced osteoporosis: How common is it among Saudi Arabian cancer survivors.
    Al Amri A; Sadat-Ali M
    Indian J Cancer; 2009; 46(4):331-4. PubMed ID: 19749464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the use of histrelin acetate in the treatment of prostate cancer.
    Crawford ED
    BJU Int; 2009 Mar; 103 Suppl 2():14-22. PubMed ID: 19228148
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study).
    Hoffman RM; Couper MP; Zikmund-Fisher BJ; Levin CA; McNaughton-Collins M; Helitzer DL; VanHoewyk J; Barry MJ
    Arch Intern Med; 2009 Sep; 169(17):1611-8. PubMed ID: 19786681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
    Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.
    Rozenberg S; Carly B; Liebens F; Antoine C
    Maturitas; 2009 Sep; 64(1):1-3. PubMed ID: 19709824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.